MASIMO CORP
About MASIMO CORP
Masimo Corp is a medical technology company. The company oepates in single segment namely Healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. The company sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2026
- $1.5B
- Net income
- -$151.5M
- Total assets
- $1.7B
- Market cap
- $9.4B
- Gross margin
- 61.9%
- Operating margin
- 20.3%
- Net margin
- -9.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.5B
- Cost of revenue
- $581.7M
- Gross profit
- $945.2M
- Operating expenses
- $635.2M
- Operating income
- $310.0M
- Income tax
- $64.9M
- Net income
- -$151.5M
- EPS (basic)
- $-2.83
- EPS (diluted)
- $-2.80
Balance sheet
- Total assets
- $1.7B
- Current assets
- $926.0M
- Total liabilities
- $977.7M
- Current liabilities
- $371.6M
- Shareholders’ equity
- $721.2M
Cash flow
- Operating cash flow
- $217.8M
- Investing cash flow
- $275.1M
- Financing cash flow
- -$520.7M
- Net cash flow
- -$28.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $9.4B
- EPS (diluted)
- $-2.8
- Shares outstanding
- 52.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 8, 2007
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $151.5M in FY2026.
- Revenue grew 34% from FY2020 to FY2025.
- Gross margin of 61.9%, net margin -9.9%.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review MASIMO CORP.
Write a review
News about MASIMO CORP
News & sentiment via Polygon.io
